Clinical Trial Update: Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial [Phase 1, Phase 2]

View source ↗

Summary

The update reports completion of a Phase I/II biomarker and safety trial of topical C-82 for systemic sclerosis (scleroderma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• Topical C-82 (C-82)

Snippet

Sponsor: Prism Pharma Co., Ltd. | Conditions: Systemic Scleroderma | Phase 1, Phase 2 | Status: COMPLETED